Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Harnessing the potential of multimodal radiotherapy in prostate cancer.

Journal article

Philippou Y. et al, (2020), Nat Rev Urol

"TREXIT 2020": why the time to abandon transrectal prostate biopsy starts now.

Journal article

Grummet J. et al, (2020), Prostate Cancer Prostatic Dis, 23, 62 - 65

Optimizing prostate biopsy techniques.

Journal article

Omer A. and Lamb AD., (2019), Curr Opin Urol, 29, 578 - 586

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: a Cochrane Review.

Journal article

Sathianathen NJ. et al, (2019), BJU Int, 124, 370 - 372

Genetic Reasons to Walk the Extra Mile to Prevent Prostate Cancer.

Journal article

Bratt O. and Lamb AD., (2019), Eur Urol, 76, 41 - 42

DESNT: A Poor Prognosis Category of Human Prostate Cancer.

Journal article

Luca B-A. et al, (2018), Eur Urol Focus, 4, 842 - 850

Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.

Journal article

Bakht MK. et al, (2018), Endocr Relat Cancer, 26, 131 - 146

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Journal article

Sathianathen NJ. et al, (2018), Cochrane Database Syst Rev, 10

Pathologist Assessment of Novel Histological Features in Prostate Cancer

Conference paper

Tupper PM. et al, (2018), JOURNAL OF PATHOLOGY, 246, S42 - S42

Load More